An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study

Timothy Davis; Wendy Davis

doi:10.2337/dc06-1704

An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study

Timothy Davis, Wendy Davis

Graduate Research School

Research output: Contribution to journal › Article

8 Citations (Scopus)

Abstract

The product information ( 1 ) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV 1)

Original language	English
Pages (from-to)	360-361
Journal	Diabetes Care
Volume	30
Issue number	2
DOIs	https://doi.org/10.2337/dc06-1704
Publication status	Published - 2007

Access to Document

10.2337/dc06-1704

Fingerprint Dive into the research topics of 'An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study'. Together they form a unique fingerprint.

Cite this

@article{fe7ef163dad241c5b42282a4f9904b29,

title = "An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study",

abstract = "The product information ( 1 ) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV 1)",

author = "Timothy Davis and Wendy Davis",

year = "2007",

doi = "10.2337/dc06-1704",

language = "English",

volume = "30",

pages = "360--361",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "2",

}

TY - JOUR

T1 - An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study

AU - Davis, Timothy

AU - Davis, Wendy

PY - 2007

Y1 - 2007

N2 - The product information ( 1 ) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV 1)

AB - The product information ( 1 ) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV 1)

U2 - 10.2337/dc06-1704

DO - 10.2337/dc06-1704

M3 - Article

VL - 30

SP - 360

EP - 361

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 2

ER -